Superior mesenteric artery thrombosis

Abbott, Ethan; Truong, Jimmy; Rada, Kristen

doi:10.1016/j.visj.2016.10.008

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arterial thrombosis has been associated with a series of pathologic conditions, such as acute coronary syndromes, [1][2][3] ischemic stroke, 4,5 transient ischemic attack, 5,6 tumor thrombosis, 7,8 recurrence of thromboembolic events, 9,10 metabolic syndrome, [11][12][13][14][15] chronic pain and swelling symptoms. 16 Platelet activation plays an important role in the formation of arterial thrombosis. 17,18 Thrombosis involves the complex interactions between coagulation, and fibrinolytic and innate immune systems, while the interaction between the platelets, injured vessel and a variety of specific membrane receptors plays an essential role.…”

Section: Introductionmentioning

confidence: 99%

Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA

Zhu

Yang

et al. 2018

IJN

View full text Add to dashboard Cite

Background Arterial thrombosis has been associated with a series of pathological conditions, and the discovery of arterial thrombosis inhibitor is of clinical importance. Methods By analyzing the pharmacophores of anti-platelet agents, thrombus targeting peptide and anti-thrombotic nano-systems 3S-1,2,3,4-tetrahydroisoquino-line-3-carbonyl-Thr-Ala-Arg-Gly-Asp(Val)-Val (IQCA-TAVV) was designed and prepared as a nano-scaled arterial thrombosis inhibitor. Results In vitro the nanoparticles of IQCA-TAVV were able to adhere onto the surface of activated platelets, attenuate activated platelets to extend pseudopodia and inhibit activated platelets to form aggregators. In vivo IQCA-TAVV targeted arterial thrombus, dose dependently inhibited arterial thrombosis with a 1 nmol/kg of minimal effective dose, and the activity waŝ1670 folds of that of aspirin. Conclusion IQCA-TAVV represented the design, preparation and application of nanomedicine capable of adhering on the surface of activated platelets, attenuating platelet activation, targeting arterial thrombus and inhibiting arterial thrombosis.

show abstract